Commentary on Austrian consensus paper on prophylaxis of the RSV-Infection with palivizumab and Post-RSV-respiratory-diseases

被引：1

作者：

Liese, J. ^{[1
]}

机构：

[1] Univ Munich, Abt Antimikrobielle Tehrapie & Infekt Immunol, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany

来源：

MONATSSCHRIFT KINDERHEILKUNDE | 2008年 / 156卷 / 04期

关键词：

D O I：

10.1007/s00112-008-1744-5

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

引用

下载

页码：384 / 384

页数：1

共 50 条

[31] A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: How can compliance be improved?
Pignotti, MS
Catarzi, S
Donzelli, G
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2006, 19 (04): : 221 - 224
[32] A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
B. Paes
I. Mitchell
A. Li
K. L. Lanctôt
European Journal of Clinical Microbiology & Infectious Diseases, 2012, 31 : 2703 - 2711
[33] A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
Paes, B.
Mitchell, I.
Li, A.
Lanctot, K. L.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (10) : 2703 - 2711
[34] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB AS A PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK LATE PRETERM INFANTS IN THE NETHERLANDS
Langenfeld, M. K.
Visser, S.
VALUE IN HEALTH, 2013, 16 (07) : A372 - A372
[35] Palivizumab for respiratory syncytial virus (RSV) prophylaxis of high-risk infants in a medicaid health maintenance organization (HMO)
Schaffer, M
Greenspan, JS
Amaya, MA
Vojta, D
PEDIATRIC RESEARCH, 2000, 47 (04) : 322A - 322A
[36] Abortive replication and reactivation in vitro respiratory syncytial virus (RSV) infection in palivizumab-treated HeLa cells
Poh, Matthew Wee-Peng
Fonceca, Angela
Kicic, Anthony
Everard, Mark
EUROPEAN RESPIRATORY JOURNAL, 2016, 48
[37] Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis
M. Cetinkaya
T. K. Oral
S. Karatekin
B. Cebeci
A. Babayigit
Y. Yesil
European Journal of Clinical Microbiology & Infectious Diseases, 2017, 36 : 1629 - 1634
[38] Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis
Cetinkaya, M.
Oral, T. K.
Karatekin, S.
Cebeci, B.
Babayigit, A.
Yesil, Y.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2017, 36 (09) : 1629 - 1634
[39] FACTORS RELATED TO RESPIRATORY SYMPTOMS IN YOUNG-CHILDREN HOSPITALIZED IN INFANCY BECAUSE OF RSV-INFECTION - A FOLLOW-UP-STUDY
FREYSCHUSS, U
ERIKSSON, M
RYLANDER, E
BULLETIN EUROPEEN DE PHYSIOPATHOLOGIE RESPIRATOIRE-CLINICAL RESPIRATORY PHYSIOLOGY, 1986, 22 : S12 - S12
[40] FACTORS RELATED TO RESPIRATORY SYMPTOMS IN YOUNG-CHILDREN HOSPITALIZED IN INFANCY BECAUSE OF RSV-INFECTION - A FOLLOW-UP-STUDY
FREYSCHUSS, U
ERIKSSON, M
RYLANDER, E
BULLETIN EUROPEEN DE PHYSIOPATHOLOGIE RESPIRATOIRE-CLINICAL RESPIRATORY PHYSIOLOGY, 1985, 21 : 59 - 59

← 1 2 3 4 5 →